Henning Hofmeister
Papers
1
Total Citations
27
H-Index
1
About
Henning Hofmeister is a dermatology researcher whose work bridges clinical immunology and advanced proteomic analysis, with a focus on inflammatory skin diseases. His key research areas include psoriasis pathogenesis, biologic therapies, and topo-proteomic methodologies for in situ protein analysis. Hofmeister’s most notable contribution is his pioneering pilot study on efalizumab, a monoclonal antibody targeting the CD11a subunit of LFA-1, in psoriasis patients. This work demonstrated that five out of six patients responded to treatment, achieving a dramatic average reduction in Psoriasis Area and Severity Index (PASI) from 21.3 to 3 over 12 weeks, with excellent tolerability. The study, which has garnered 27 citations, provided early evidence for the therapeutic potential of LFA-1 blockade and showcased Hofmeister’s innovative use of topo-proteomic techniques to analyze protein distribution in psoriatic plaques. By integrating clinical outcomes with molecular profiling, Hofmeister has contributed to a deeper understanding of psoriasis pathophysiology and the mechanisms of targeted immunotherapy. His work continues to inform the development of more precise treatments for chronic inflammatory conditions.
Research Focus
Key Achievements
Top Papers
- 1